Dr. Perez-Soler on Impact of Osimertinib on Field of NSCLC

Roman Perez-Soler, MD
Published: Saturday, Nov 12, 2016



Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, Albert Einstein College of Medicine of Yeshiva University, discusses the impact of osimertinib (Tagrisso) on patients with T790M-positive non–small cell lung cancer (NSCLC).

Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, has had a significant impact on the landscape since its FDA approval, Perez-Soler explains. This agent is able to target the significant number of patients who develop acquired T790M resistance to EGFR-targeted therapies.

Additionally, osimertinib is not associated with some of the toxicities frequently reported with EGFR inhibitors, including rash. Perez-Soler also explains that osimertinib has demonstrated higher levels of efficacy than gefinitib (Iressa), erlotinib (Tarceva), and afatinib (Gilotrif). Patient quality of life is also significantly improved on this agent, he says.

<<< View more from the 2016 New York Lung Cancer Symposium


Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, Albert Einstein College of Medicine of Yeshiva University, discusses the impact of osimertinib (Tagrisso) on patients with T790M-positive non–small cell lung cancer (NSCLC).

Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, has had a significant impact on the landscape since its FDA approval, Perez-Soler explains. This agent is able to target the significant number of patients who develop acquired T790M resistance to EGFR-targeted therapies.

Additionally, osimertinib is not associated with some of the toxicities frequently reported with EGFR inhibitors, including rash. Perez-Soler also explains that osimertinib has demonstrated higher levels of efficacy than gefinitib (Iressa), erlotinib (Tarceva), and afatinib (Gilotrif). Patient quality of life is also significantly improved on this agent, he says.

<<< View more from the 2016 New York Lung Cancer Symposium

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x